Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL).
Anthracyclines
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cell Transformation, Neoplastic
Combined Modality Therapy
Disease-Free Survival
Humans
Italy
/ epidemiology
Lymphoma, Follicular
/ mortality
Retrospective Studies
Rituximab
/ administration & dosage
Stem Cell Transplantation
/ methods
Transplantation, Autologous
Treatment Outcome
Watchful Waiting
composite lymphoma
autologous stem cell transplantation
follicular lymphoma
histological transformation
rituximab maintenance
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
23
09
2018
accepted:
02
01
2019
pubmed:
23
2
2019
medline:
2
5
2020
entrez:
23
2
2019
Statut:
ppublish
Résumé
Optimal treatment for transformed follicular lymphoma (tFL) is not fully defined. Clinical characteristics and treatments that impact on post-transformation outcome of 176 biopsy-proven tFL were analysed. Transformation occurred at initial diagnosis in 52% (Group 1) and after a FL diagnosis in 48% (Group 2). Five-year overall survival was 84% for Group 1 and 51% for Group 2 (P < 0·001). In Group 1, 5-year progression-free survival was superior after rituximab maintenance compared to observation only (94% vs. 53%, P = 0·024). In Group 2, an inverse trend was found between survival and both a higher number of pre-transformation treatment lines and a short time-to-transformation.
Substances chimiques
Anthracyclines
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
713-717Informations de copyright
© 2019 British Society for Haematology and John Wiley & Sons Ltd.